AbbVie (ABBV) shares reached a record high of $238.71 on October 1, 2025, but have since retreated approximately 13%. This pullback may present a compelling buying opportunity for long-term investors willing to overlook short-term volatility. The decline follows a substantial rally, fueled by optimism surrounding its immunology drugs, Skyrizi and Rinvoq, which are expected to offset declining revenues from the blockbuster drug Humira.
The recent downturn can be attributed to rising macroeconomic pressures, including concerns over sustained high interest rates, which have impacted high-yield dividend stocks like AbbVie. Investors may have opted to take profits amid fears of regulatory challenges and slower-than-anticipated growth for its new drug portfolio. Nonetheless, AbbVie remains a solid dividend play, boasting a forward yield of 3.3% and projected earnings per share growth of over fivefold from 2025 to 2028.
For market professionals, AbbVie’s current valuation at 24 times this year’s earnings, combined with its robust dividend, positions it as an attractive option for those seeking stability in a turbulent market.
Source: fool.com